Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

— Presentation entitled BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility — — First-in-human Phase 1 trial for lead program, BMB-101,... | April 10, 2023

Related Keywords

Australia ,Adelaide ,South Australia ,United Kingdom ,Vancouver ,British Columbia ,Canada ,Canadian ,British ,Ian Mcdonald ,Alex Vasilkevich ,Lisa Wilson ,John Mccorvy ,Neither The Canadian Securities Exchange ,Bright Minds Biosciences Inc ,International Society For Serotonin Research ,Regulation Services Provider ,International Meeting ,Clinical Research ,Globenewswire Inc ,First In Human Phase ,Minds Biosciences ,Bright Mind Scientific Officer ,Serotonin Research ,Senior Advisor ,Scientific Officer ,Dravet Syndrome ,Canadian Securities Exchange ,Bright Minds Biosciences Inc Stock Exchange ,News ,Information ,Press Release ,Ntitled ,Elective ,Agonist ,N ,Linical ,Trials ,Ith ,Herapeutic ,Hase , ,Trial ,Or ,Ead Drug Ca10919w1086 ,